BFF
BMRN icon

Byrne Financial Freedom’s BioMarin Pharmaceuticals BMRN Stock Holding History

Byrne Financial Freedom’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,852
Closed -$212K – 100
2025
Q2 		$212K Hold
3,852
– – 0.11% 92
2025
Q1 		$272K Buy
3,852
+161
+4% +$10.8K 0.15% 80
2024
Q4 		$243K Buy
+3,691
New +$247K 0.11% 87

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Byrne Financial Freedom's BMRN Position: Q3 2025 in Review

Byrne Financial Freedom sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 3,852 shares — an estimated $212K sold.

Byrne Financial Freedom first reported a position in BMRN in Q4 2024 and held it in 3 quarters. The position peaked at $272K in Q1 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Byrne Financial Freedom reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Byrne Financial Freedom sold 3,852 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $212K.
  • Byrne Financial Freedom first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Byrne Financial Freedom's BioMarin Pharmaceuticals position peaked at $272K in Q1 2025.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Byrne Financial Freedom's 13F filing for Q3 2025, filed 14 Nov 2025.